# Pizarra — PT-pseudo_cce5d47c05dd (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_cce5d47c05dd
Task: 1

Encounter: Urology - outpatient on 17 Jan 2025.
Referrer: Dr. R. Visser (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 61-year-old male
  - PSA: 12.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.28 ng/mL²
  - PSA velocity: 3.98 ng/mL/yr
  - Prior PSA: 7.0 ng/mL
  - Prostate volume: 42.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8442586 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Obesity (BMI >30), Osteoarthritis
  - Problem list / PMHx: Obesity (BMI >30), Osteoarthritis
  - Current medication: paracetamol PRN
  - Allergies: Penicillin (rash)
  - Additional notes: PSA 12 ng/mL. PI-RADS 5. PSAD 0.28. Prostate volume 42 mL. csPCa 0.84.

Vitals: weight 86 kg, height 173 cm, BMI 28.7, BP 109/68 mmHg, HR 59 bpm. Smoking: Non-smoker.

Chief complaint: Clinician seeks re-evaluation due to a sustained PSA elevation and a previous biopsy documenting ISUP Grade Group 2 adenocarcinoma.

History: This 61-year-old individual was first evaluated in 2022 after an unexpected PSA elevation surfaced. A subsequent targeted biopsy confirmed disease, with the prior biopsy bucket "Positive", and he now attends for routine surveillance. He reports persistent lower urinary tract symptoms, recording an IPSS score of 20 mainly due to nocturia and a diminished stream, which he currently manages with paracetamol PRN. A retired postal worker, he maintains an active lifestyle that includes weekend hiking and is Married, Lives with partner. His Osteoarthritis remains controlled, and he recently visited podiatry for routine nail care without incident. He is a Non-smoker and maintains Obesity (BMI >30). He explicitly denies unexplained weight loss, bone pain, or haematuria, and abstains completely from alcohol.

Physical examination: Normal DRE; the prostate presents with a symmetrically enlarged, firm, and smooth contour without asymmetry or palpable nodules. General inspection shows stable vital parameters and absence of abdominal masses or lymphadenopathy. Ambulation is independent, although mild bilateral knee crepitus correlates with his established condition.

Patient info: retired postal worker; Married; Lives with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Hiking on weekends; IPSS score: 20/35 (severe LUTS).

Recent other appointments: Podiatry — routine foot care.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.57 +/- 0.20   (95% CI 0.18-0.92)

Where the uncertainty comes from:
  - aleatoric  dA = 0.15  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.13  (few labelled cases resemble this one)
  - 6.7 effective neighbours out of 10; 2 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=12.0, age=61.0, psad=0.28, dre_ord=0.0, vol=42.0, n_pmhx=2.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel data (PI-RADS=5, PSA=12.0, prior positive biopsy, csPCa probability=0.844) and could not weigh the clinical context, such as the specific ISUP grade of the prior diagnosis or the specific findings from the retrieved MRI report or laboratory panel.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy with a 57% probability, which is in the 'discuss' tier, meaning the classifier cannot distinguish between the two outcomes. This is problematic because the protocol expert stated the decision is undetermined by the visible panel, and the prior failed to incorporate the crucial missing context from the retrieved documents. Furthermore, the prior did not account for the specific PSA density (0.28 ng/mL²) or the specific PI-RADS 5 score in relation to the guideline's risk matrix.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
laboratory panel - what are the specific lab values?
previous GP / urology consultation notes - what was the specific ISUP grade of the prior diagnosis?
radiology report - does the lesion compare with a previous MRI?

GUIDELINE ANCHOR
The guideline suggests that the decision must be based on whether the prior grade is documented, whether the lesion changed against a previous MRI, and whether a surveillance re-biopsy is due.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_cce5d47c05dd", "radiology_report": "Maastricht UMC+ | Radiology | 10 January 2025 | Multiparametric MRI of the Prostate\nClinical Context: Rising prostate-specific antigen (12.0 ng/mL) noted alongside a previous biopsy documenting Gleason 3+4 (ISUP 2). PSA velocity stands at 3.98 ng/mL/yr.\nRESULTS: The gland measures 42.0 mL overall. T2-weighted imaging isolates a focal, hypointense focus roughly 12 x 10 mm situated in the right mid-gland peripheral zone. High b-value DWI shows intense restricted diffusion, mirrored by low ADC signal. DCE sequences highlight rapid, early enhancement followed by prompt washout. Bilateral neurovascular bundles remain preserved. There is no evidence of seminal vesicle invasion, extraprostatic extension, or suspicious pelvic lymphadenopathy.\nCONCLUSION: PI-RADS 5 lesion located in the right mid peripheral zone. PSAD 0.28 ng/mL/mL. csPCa predicted probability 0.8442586."}
get_psa_trend
{"case_id": "PT-pseudo_cce5d47c05dd", "psa_trend": [{"date": "Jun 2022", "val": 1.8}, {"date": "Sep 2023", "val": 4.6}, {"date": "Jan 2025", "val": 12.0}]}
get_previous_notes
{"case_id": "PT-pseudo_cce5d47c05dd", "previous_notes": [{"date": "19 Sep 2024", "author": "Dr. R. Visser (GP)", "text": "Patient attended for routine follow-up after the initial biopsy yielded Gleason 3+4 pathology. Recent laboratory work shows a PSA increase from 7.0 ng/mL in September 2023 to 10.5 ng/mL, which led to scheduling a repeat mpMRI and specialist review. Lower urinary tract symptoms remain bothersome, though no new systemic issues were reported. The complete clinical dossier along with imaging requisitions was transmitted to the urology outpatient department for continued evaluation."}]}
get_lab_results
{"case_id": "PT-pseudo_cce5d47c05dd", "laboratory_results": [{"name": "PSA", "val": "12.0 ng/mL", "date": "20 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "3.24 ng/mL", "date": "20 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "27%", "date": "20 Dec 2024", "flag": ""}, {"name": "Haemoglobin", "val": "14.2 g/dL", "date": "20 Dec 2024", "flag": ""}, {"name": "WBC", "val": "6.1 x10^9/L", "date": "20 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "229 x10^9/L", "date": "20 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "86 umol/L", "date": "20 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "20 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "9.7 nmol/L", "date": "20 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "49 U/L", "date": "20 Dec 2024", "flag": ""}, {"name": "LDH", "val": "164 U/L", "date": "20 Dec 2024", "flag": ""}]}

NOT RETRIEVED
The specific ISUP grade of the prior diagnosis was not explicitly documented in the retrieved notes, only "Gleason 3+4 (ISUP 2)" was mentioned in the MRI context.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion located in the right mid peripheral zone.
- PSA trend: Rising from 4.6 ng/mL (Sep 2023) to 12.0 ng/mL (Jan 2025), with a velocity of 3.98 ng/mL/yr.
- Previous notes: Patient was scheduled for a repeat mpMRI and specialist review following a PSA increase.

AGAINST sampling this patient now:
- Previous notes: Patient is currently on routine surveillance.
- MRI report: No evidence of seminal vesicle invasion, extraprostatic extension, or suspicious pelvic lymphadenopathy.

WHERE THIS LEANS
The evidence strongly suggests a need for further investigation due to the high-risk MRI finding (PI-RADS 5) and the significant PSA velocity, which contradicts the protocol expert's finding that the panel is undetermined.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: uncertain)

Although the patient has a prior positive biopsy, the retrieved documents do not explicitly document the specific ISUP grade of the prior diagnosis, which is a key factor for deciding on surveillance. The high PI-RADS 5 score and the significant PSA velocity (3.98 ng/mL/yr) suggest that the current findings warrant further tissue sampling to guide definitive management. Since the record is silent on whether the prior grade is fully characterized, proceeding with a biopsy is necessary to establish the current pathological status.

Variables that carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=important, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
